Gary Yeung, CFA

Moonwalk Biosciences is pioneering novel therapeutics in adipose biology and tissue, driven by deep genetic and epigenetic evidence and insights. It utilizes its discovery platform to identify novel targets involved in obesity and cardiometabolic disease, and is advancing an early stage pipeline of therapeutic candidates.

TRIANA Biomedicines is a venture-backed biopharmaceutical company leading a transformative approach to discover and develop novel small molecules to treat disease. Our technology enables us to identify molecules that promote the interaction between a target and another protein in a way that alters the fate or function of the target protein. These innovative “molecular glues” allow us to treat disease in entirely new ways by pursuing highly disease relevant targets that have long been considered undruggable or are inadequately addressed. Our target-first, rational approach to molecular glue discovery lets us consider a wide-range of therapeutic applications for our products. Our initial focus on targeted protein degradation is driven by our desire to discover and develop groundbreaking new cancer medicines. TRIANA Biomedicines is headquartered in Waltham, Massachusetts, and has established internal laboratory work as well as key collaborations with academia and industry partners.

Protego Bio is a clinical-stage company focused on the discovery and development of first-in-class small-molecule therapeutics that aim to reprogram protein folding for the treatment of various diseases. We are exploring monogenetic protein misfolding diseases that cause myopathy, cardiomyopathy, stroke, renal disease, retinal diseases, channelopathies, and various degenerative diseases. Our approach builds on the proven pharmacological chaperone strategy exemplified by tafamidis, which was discovered and developed by our cofounders, Dr. Jeffery W. Kelly and Dr. Richard Labaudinière, for the treatment of transthyretin amyloidosis.

Biotech R&D

Neurona is a biotherapeutics company developing neural cell therapies with single-dose curative potential for the treatment of chronic neurological disorders. Based on a novel neural cell lineage pioneered by the company’s scientific founders, Neurona has built a robust regenerative platform and is developing neuronal, glial, and gene-edited cell therapy candidates that provide long-term repair of dysfunctional neural networks for multiple neurological disorders. For more information about Neurona visit our website.

Axent Biosciences develops next generation stem cell therapies to address unmet medical needs in human health. Spun out of Prof. David Schaffers Lab at UC Berkeley, Axents platform technologies in stem cell manufacturing and implantation leverage 20+ years of stem cell expertise and 10+ years of biomaterials engineering to overcome major bottlenecks in the clinical development pipeline to efficiently provide high quality stem cell therapeutics to large populations of patients in need.

Duke Capital Partners, Duke Universitys official early-stage venture investment arm, provides capital and expertise to help Duke startups, and features one of Duke’s most innovative experiential learning opportunities for students. As one of the largest and oldest university investment entities of its kind, Duke Capital Partners consistently places among the top five in North America. Our mission is to support the global Duke entrepreneurial community with an angel investing platform and co-investment fund (the Duke Innovation Fund) that engage and leverage the unparalleled Duke network.

Moonwalk Biosciences is pioneering novel therapeutics in adipose biology and tissue, driven by deep genetic and epigenetic evidence and insights. It utilizes its discovery platform to identify novel targets involved in obesity and cardiometabolic disease, and is advancing an early stage pipeline of therapeutic candidates.

TRIANA Biomedicines is a venture-backed biopharmaceutical company leading a transformative approach to discover and develop novel small molecules to treat disease. Our technology enables us to identify molecules that promote the interaction between a target and another protein in a way that alters the fate or function of the target protein. These innovative “molecular glues” allow us to treat disease in entirely new ways by pursuing highly disease relevant targets that have long been considered undruggable or are inadequately addressed. Our target-first, rational approach to molecular glue discovery lets us consider a wide-range of therapeutic applications for our products. Our initial focus on targeted protein degradation is driven by our desire to discover and develop groundbreaking new cancer medicines. TRIANA Biomedicines is headquartered in Waltham, Massachusetts, and has established internal laboratory work as well as key collaborations with academia and industry partners.

Protego Bio is a clinical-stage company focused on the discovery and development of first-in-class small-molecule therapeutics that aim to reprogram protein folding for the treatment of various diseases. We are exploring monogenetic protein misfolding diseases that cause myopathy, cardiomyopathy, stroke, renal disease, retinal diseases, channelopathies, and various degenerative diseases. Our approach builds on the proven pharmacological chaperone strategy exemplified by tafamidis, which was discovered and developed by our cofounders, Dr. Jeffery W. Kelly and Dr. Richard Labaudinière, for the treatment of transthyretin amyloidosis.

Biotech R&D

Neurona is a biotherapeutics company developing neural cell therapies with single-dose curative potential for the treatment of chronic neurological disorders. Based on a novel neural cell lineage pioneered by the company’s scientific founders, Neurona has built a robust regenerative platform and is developing neuronal, glial, and gene-edited cell therapy candidates that provide long-term repair of dysfunctional neural networks for multiple neurological disorders. For more information about Neurona visit our website.